The Prostate Net
 
About Us
Store
In the Know Awards
Barbershop Initiative®
Programs
Press & News
DONATE
Locate a Physician
Podcast
Patient Support
Treatment Options
The Knowledge Net
Newsletter
Contact Us

 

The Prostate Net®Inc.
P. O. Box 10188-#77550
Newark, NJ 07101-3188
Tel: 1.201.289.8221
Fax: 1.270.294.1565

support@prostatenet.org

This website is certified by Health On the Net Foundation. Click to verify.

This page was
 

Chemotherapy

The Food and Drug Administration has approved Taxotere® (docetaxel) for use in combination with prednisone as a treatment for men with androgen-independent (hormone-refractory) metastatic prostate cancer. Taxotere, a drug in the taxoid class of chemotherapeutic agents, inhibits cancer cell division by essentially "freezing" the cell's internal skeleton, which is comprised of microtubules. Microtubules assemble and disassemble during a cell cycle. Taxotere promotes their assembly and blocks their disassembly, thereby preventing many cancer cells from dividing and resulting in cancer cell death.

The importance of this event is that it defines Taxotere® as the first drug approved for treating advanced prostate cancer that has shown a survival benefit. Information on the clinical studies of Taxotere can be seen in our Clinical Research section. An article by Dr. Daniel Petrylak on one of the studies can be seen in our "In The Know" newsletter. Additional information on the drug can be found here.

Additional clinical investigations are on-going using Taxotere with estramustine (Emcyt) because the estrogen-like activity of estramustine can increase the efficacy of Taxotere thereby potentially extending the survival period.

Additional trials to evaluate the drug's effectiveness in treating hormone refractory prostate cancer have combined Taxotere with other agents such as, Thalomid, Xinlay, Revlimid, samarium (Quadramet), calcitriol and epirubicin among many others. Details on much of the research being done can be seen here

Even more exciting is the research being done using Taxotere as an early stage treatment for prostate cancer either as a single agent or neoadjuvantly prior to radical prostatectomy surgery. A commentary by Dr. Michael Carducci of Johns Hopkins can be seen here.

Click here to learn more about Taxotere

 

 

Go to:

Alternative Medicine

Chemotherapy

Clinical Trials

Cytotoxic Therapy

Diagnostics

Hormones

Informed Decision Making

Pain Management

Palliative Care

Radiation Solutions

Dealing with Side Effects

Surgical Solutions

Targeted Therapies

Translational Research

Active Surveillance

 

For Email Newsletters you can trust

Home | About Us | Store | In the Know Newsletter | Barbershop Initiative | Programs | Press & News | DONATE | Locate a Physician | Podcast | Treatments Options | The Knowledge Net | Contact Us

Site Designed by:
Marshall Haber Creative Group inc.